Surjit Pal

Jump to

Ranbaxy may suffer loss of $250 mn on approval woes: Expert

Surajit Pal, pharma analyst, Prabhudas Lilladher, expects Teva, Mylan, Sandoz and Dr Reddy‘s Laboratories to benefit from this loss.
USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert

The USFDA today approved Ranbaxy‘s drug called Plendil generic, which is used for hypertension. Ranbaxy was expected to be the authorised generic for this particular drug, but it is already genericised and there are already 6-7 players in this market for this particular drug.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Surjit Pal

Ranbaxy may suffer loss of &#36;250 mn on approval woes: Expert

USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert

Ranbaxy may suffer loss of $250 mn on approval woes: Expert